There is substantial variation in the dose of warfarin required to achieve therapeutic anticoagulation. In this study, mathematical models for warfarin dosage were constructed that used either clinical factors alone or clinical and genetic factors. The model incorporating genetic factors, when tested retrospectively with data from an international cohort, provided better estimates than a model that included only clinical factors.

Isocitrate dehydrogenases, encoded by the IDH1 and IDH2 genes, catalyze the reduction of NADP⁺ to NADPH in the brain. One or the other of these two genes was found to be mutated in 70% of 445 gliomas of World Health Organization grade II or III. The mutations abolished the enzymatic activity of the IDH1 and IDH2 proteins. The evidence suggests that mutation of an IDH gene is an early event in the development of gliomas.

This substudy of the Occluded Artery Trial, in which high-risk patients with an occluded infarct-related artery who were in stable condition were randomly assigned to percutaneous coronary intervention (PCI) or medical therapy alone, showed a marginal advantage in cardiac physical functioning in the medical-therapy group at 4 months but not thereafter; costs were higher and quality-adjusted survival was marginally lower in the PCI group.